In the randomized phase III POSEIDON trial, patients with advanced NSCLC were randomized into three arms to receive tremelimumab (anti-CTLA-4) plus durvalumab (anti-PD-L1) plus chemotherapy; durvalumab plus chemotherapy; or chemotherapy alone as first-line treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.